How does the biorepository work?
The COVID-19 biorepository supports the prospective collection of biospecimens and associated de-identified data from hospitalized patients under one standardized protocol. The centralized nature of the biorepository ensures uniform specimen handling, data quality, and regulatory oversight for biobanking operations. Specimens are collected at multiple time points and include nasopharyngeal, oropharyngeal and rectal swabs as well as plasma, serum, peripheral blood mononuclear cells (PBMC), placentae, saliva, urine and stool.
Who can apply to use COVID-19 biorepository specimens and accompanying de-identified data?
The COVID-19 biorepository is available to qualified investigators within the Tufts Medical Center and Tufts University research community as well as qualified investigators from MassCPR. Not all specimen types may be available from all participants.
Who decides how specimens are shared?
The COVID-19 Biorepository Oversight Committee will grant approval to investigators who have relevant Research Committee, Biosafety and Institutional Review Board (IRB) approvals. Specimen access is on a first come first served basis.